Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. Moriyama S, et al. Among authors: nojima k. Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2. Immunity. 2021. PMID: 34246326 Free PMC article.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: nojima k. Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4. Med. 2022. PMID: 35261995 Free PMC article.
Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S, Wagatsuma A, Numata N, Sasaki K, Kuzuoka T, Yato Y, Takahashi Y, Maeda K, Suzuki T, Mizukami T, Hamaguchi I. Seki Y, et al. Among authors: nojima k. Med. 2022 Jun 10;3(6):406-421.e4. doi: 10.1016/j.medj.2022.04.013. Epub 2022 Apr 26. Med. 2022. PMID: 35815933 Free PMC article.
Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in Japan.
Shimbashi R, Shiino T, Ainai A, Moriyama S, Arai S, Morino S, Takanashi S, Arashiro T, Suzuki M, Matsuzawa Y, Kato K, Hasegawa M, Koshida R, Kitaoka M, Ueno T, Shimizu H, Yuki H, Takeda T, Nakamura-Uchiyama F, Takasugi K, Iida S, Shimada T, Kato H, Fujimoto T, Iwata-Yoshikawa N, Sano K, Yamada S, Kuroda Y, Okuma K, Nojima K, Nagata N, Fukushi S, Maeda K, Takahashi Y, Suzuki T, Ohnishi M, Tanaka-Taya K. Shimbashi R, et al. Among authors: nojima k. Glob Health Med. 2023 Feb 28;5(1):5-14. doi: 10.35772/ghm.2022.01060. Glob Health Med. 2023. PMID: 36865900 Free PMC article.
Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval.
Miyamoto S, Kuroda Y, Kanno T, Ueno A, Shiwa-Sudo N, Iwata-Yoshikawa N, Sakai Y, Nagata N, Arashiro T, Ainai A, Moriyama S, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Fukushi S, Takahashi Y, Maeda K, Suzuki T. Miyamoto S, et al. Among authors: nojima k. iScience. 2023 May 19;26(5):106694. doi: 10.1016/j.isci.2023.106694. Epub 2023 Apr 19. iScience. 2023. PMID: 37124417 Free PMC article.
Establishment of a reference material for standardization of the anti-complementary activity test in intravenous immunoglobulin products used in Japan: A collaborative study.
Nojima K, Okuma K, Ochiai M, Kuramitsu M, Tezuka K, Ishii M, Ueda S, Miyamoto T, Kamimura K, Kou E, Uchida S, Watanabe Y, Okada Y, Hamaguchi I. Nojima K, et al. Biologicals. 2017 Mar;46:68-73. doi: 10.1016/j.biologicals.2016.12.008. Epub 2017 Feb 3. Biologicals. 2017. PMID: 28162840
200 results